# **Curriculum Vitae**



Name	Hatem A Hejaz (Full Professor)		
Gender	Male		
Nationality	Palestinian		
Postal Address	Department of Pharmacy, Faculty of Pharmacy		
	Arab American University,		
	P.O Box 240 Jenin, 13 Zababdeh		
	Jenin - Palestine		
	<b>Tel:</b> (970)-4-2418888, <b>Fax:</b> (970)-4-2510810, <b>Mobile:</b> (970)-599-132862		
	E-mail: <u>hatem.hijaz@aaup.edu</u> or <u>hatem_hejaz@yahoo.com</u>		
Orcid ID	http://orcid.org/0000-0001-8757-133X		
<b>Research Gate</b>	https://www.researchgate.net/profile/Hatem-Hejaz		
Google Scholar	https://scholar.google.com/citations?user=KFn4Dh8AAAAJ&hl=en		
Scopus ID	6507461258 or 57105438100		
AD Scientific Index	https://www.www.adscientificindex.com/scientist.php?id=337230		
LinkedIn	https://www.linkedin.com/in/hatem-a-hejaz-68237241/		

## Education: -

•Ph.D.; School of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, England, UK. December 1998.

•M.Pharm. (*Pharmaceutical Chemistry*), Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Vanarasi- 221005, India, May 1995; (*First Class with distinction*).

•B.Pharm., Birla Institute of Technology, Mesra, Ranchi 835215, Bihar, India, May 1993; (First Class with honor).

•An-Najah National University, Nablus, Palestine, 1986-1989.

•General Secondary Education Certificate (Scientific Stream), Anabta High School, Anabta, West Bank, Palestine. July 1986.

## Thesis, Dissertation, and Projects: -

•**Ph.D.** (**Thesis**): Synthesis of Steroidal and Non-Steroidal Steroid Sulphatase Inhibitors for Endocrine Therapy of Breast Cancer.

•M.Pharm. (Dissertation): Synthesis and Antibacterial Activity of Some *N*-Mannich Bases of Isatin  $\beta$ -(4'-Aldehyde-2'-Thiosemicarbazone derivatives).

•**B.Pharm.** (graduation project): The Pharmacognostical, Phytochemical and Pharmacological Investigations of Solanum Indicum<sub>Linn.</sub> and Solanum Surattense <sub>Burm j</sub> Based on Their Ethno- Medicinal Values.

# Working Experience and Training: -

•Professor; Department of Pharmacy, Faculty of Pharmacy, Arab American University, Jenin, since 2/1/2024- till now.

•Dean; Department of Pharmacy, Faculty of Pharmacy, Arab American University, Jenin, since 1/9/2022- till now.

•Associate Professor; Department of Pharmacy, Faculty of Pharmacy, Arab American University, Jenin, since 1/9/2022-1/1/2024.

•Associate Professor; Department of Pharmacy, College of Pharmacy & Medical Sciences, Hebron University, Hebron, 26/8/2018- 31/8/2022.

•Dean; College of Pharmacy & Medical Sciences, Hebron University, Hebron, 25/8/2019-20/2/2021.

•Associate Professor; Department of Pharmacy, Faculty of Pharmacy, Nursing & Health professionals

Birzeit University, Birzeit, 5/9/2017-26/8/2018.

•Associate Professor; Faculty of Pharmacy; Al-Quds University; Abu Dees-Jerusalem, 1/9/07-1/9/2017.

•Dean, Faculty of Pharmacy; Al-Quds University; Abu Dees-Jerusalem; 1/8/2012- 1/9/2014.

•Assistant Dean, Faculty of Pharmacy; Al-Quds University; Abu Dees-Jerusalem, 1/8/2011-1/8/2012.

•Associate Professor, 15/04/06-1/9/07; Riyadh College of Dentistry & Pharmacy; Riyadh-Kingdom of Saudi Arabia. (Website: <u>http://www.riyadh.edu.sa</u>) & Chairman of Pharmacy & Medical Laboratory Technology Department; 12/7/2006-1/3/2007.<u>http://www.pcdp.edu.sa/index.php?id=16&childof=38&lang=en</u>

•Head of Pharmaceutical Chemistry Department (*Associate Professor*); 1/9/2004- 01/05/2006; The Specialized Pharmaceutical Research Co. Ltd. (STD); *Hikma Group*; Amman-Jordan (Website: http://www.specializedpharma.com)

•Assistant Professor; Al-Ahliyya Amman University, Faculty of Pharmacy & Medical Sciences; Amman-Jordan. 1/9/03-1/9/2004.

•Assistant Professor; Ajman University of Science & Technology, Faculty of Pharmacy & Health Sciences; Ajman-UAE. 1/9/2000-1/9/2003;

•Assistant Professor; Dubai Pharmacy College, Dubai, UAE, 22/01/2000-1/9/2000.

•Postdoctorate (*Research Officer*); Department of Pharmacy and Pharmacology, University of Bath, Bath, England, UK. 1/1/1999-18/1/2000 (Part-time: from 1/1/99-1/6/99; Full-time: from 1/6/1999-18/1/2000).

•Department of Pharmacy and Pharmacology, University of Bath, Bath, England, UK. Research in Breast Cancer; Synthesis of Steroidal and Non-Steroidal Steroid Sulphatase Inhibitors). October 1995-May 1999.

•Demonstration for undergraduate students, Department of Pharmacy and Pharmacology, University of Bath, Bath, England, UK, October 1995- March 1999.

•**Pharmacist**; Jerusalem Pharmaceuticals Co. Ltd., Ramallah- West Bank; Research and Development Department, April 1, 1995- August 20, 1995.

•Training; Dar Al-Dawa Co. Ltd.- Amman- Jordan (Pharmaceutical Company), June- August 1991.

•1444 hours (~ Six Months) in community Pharmacy in Jordan, pre-registration requirement to practice Pharmacy in Jordan. 1992-1994 (part-time).

## **Research Programs:**

A) Identification of bitter taste antagonists *and* Elucidation of interactions between bitter taste receptors and their agonists: The project aim: to improve the molecular understanding of bitterness and provide potential ways to modulate the activity of bitter taste receptors. As a result of this research, we expect to a) gain a better understanding of the structure-function relationships of bitter taste receptors and b) develop candidates for bitter taste inhibition. Such inhibitors will be of great importance and value to the

pharmaceutical and, most likely, food industries, since they will be able to eliminate the aversive taste of medicine and foods and should therefore result in better patient compliance in taking medicines, as well as increased consumer acceptance of healthy, but bitter vegetables and fruits. This has tremendous potential implications for the pharmaceutical and food industries. As the role of taste receptors in food-intake regulation is being unraveled, agonists and antagonists of bitter taste receptors will have additional important roles in modulating food intake and metabolism.

- **B**) Steroid-based enzyme inhibitors as novel therapeutic agents: Many common types of cancer (e.g. breast and prostate) are initially dependent on hormones (*e.g. estrogen and androgen*) to support their growth. However, hormone-dependent forms of such cancers usually eventually lose their requirement for hormones and, in common with their other types of malignancies (e.g. melanomas, sarcomas, etc.) continue to proliferate in a hormone-independent manner. Inhibition of the enzyme steroid sulphatase (*an enzyme that regulates the biosynthesis of estrogen*), has discovered a novel class of super-potent time and concentration-dependent active site director inhibitors. These steroid conjugates, which function by effecting irreversible active site sulphamoylation, are strong candidates as potential therapeutic agents e.g. breast cancer, Alzheimer's disease, and auto-immune diseases. They have also recently been demonstrated to be a novel class of super-estrogens for oral contraception and hormone replacement therapy. Our strategy is based around the *design and development* of novel related non-steroidal compounds and overcomes the problems (e.g. side effects, toxicity, irreversibility, estrogenicity, selectivity...etc.) associated with the steroidal drugs.
- C) Drug Discovery from medicinal plants and Natural sources, Prodrugs, overcome the various problems of exciting drugs and for other research Fields (Please See also the Publications)
- GC-MS Analysis of the Secondary Metabolites from the Leaves of Wild/ Cultivated Salvia palaestina and their in vitro Antioxidant and Antimicrobial Activities: The aim of the study to screen Palestinian S. palaestina secondary metabolites and minerals by using SD-GC-MS and ICP-OES and to examine some of their pharmacological activities. Test will include anti-oxidant, anti-bacterial and anti-fungal biological activities.
- **Biological activities and Nutritional Composition of Zingiber officinale Roscoe Rhizomes:** The identification and quantification of chemical constituents of the isolated ginger essential oil will be determined by gas chromatography and mass spectrometry GC-MS. Antioxidant activity will be determined *in vitro* using FRAP assay, and anti-bacterial effects will be evaluated on four different strains of human bacteria. The minimum inhibitory concentrations (MICs) will be and the total phenolic content will be determined.
- **Biological activities of Rhus coriaria L. (Sumac) Extracts:** The aim of this project is to evaluate the possible anticoagulant effect of Rhus coriaria extracts using blood samples of normal individuals by prothrombin time (PT) test. Also, describe and evaluate the antioxidant and phytochemical effects of Sumac.
- *Biological activities and Nutritional Composition of Essential Oil from Salvia Rosmarinus Leaves:* The study aims to screen Palestinian Rosmarinus officinalis L. secondary metabolites and minerals by using GC-MS and to examine their pharmacological activities which include anti-oxidant, anti-bacterial, and anti-fungal biological activities.

#### **D) Clinical Research (Research in progress):**

- Hematologic parameters in patients with COVID-19 infection, *Prospective study*.
- Prevalence of Depression and Associated Risk Factors Among Palestinian Adults with Diabetes Mellitus: *A cross-sectional study*
- The Prevalence of Obesity in Palestine: A cross-sectional study
- Patient Knowledge and Use of Acetaminophen: A cross-sectional study
- Anxiety among Palestinian type 2 diabetic patients and their correlation with diabetes control: A crosssectional study

#### F) Research projects/ proposals under evaluation:

- Masking bitter taste of Azithromycin & Clarithromycin and *in Vitro* Kinetics Studies
- Synthesis, Characterization, and in Vitro Kinetics of Novel L-Dopa Prodrugs
- Steroid Sulphatase Inhibitors for Endocrine Therapy of Breast Cancer
- The anti-diabetic effect of Sonchus oleraceus L extracts

# Publications & Patents:-

•Bara Asfour, Mohammad R Asia, **Hatem A Hejaz.** Exploring the effect of the Gaza-Israeli War on the Healthcare Costs and Access to Medicine in Gaza. Eastern Mediterranean Health Journal **2025**, *Submitted*.

•Hatem A Hejaz. The Influence of Gaza-Israeli War on Diabetes Treatment and Medication Adherence in Gaza. Eastern Mediterranean Health Journal 2025, *Accepted*.

• Hejaz HA. Cross-sectional investigation of the effects of the war in Gaza on quality-of-life of breast cancer patients. East Mediterr Health J. 2025;31(2):101–108. https://doi.org/10.26719/2025.31.2.101.

•Hejaz HM, Ali Makhammra JM. Identification and Quantification of Rosmarinus officinalis L. Leaf Extract Phytochemical Profiles Using Gas Chromatography-Mass Spectrometry. Asian Journal of Biological Sciences. 2024; 17(3): 433-447. <u>https://doi.org/10.3923/ajbs.2024.433.447</u>.

• Makhammra, Jummana M.; Basheer-Salimia, Rezq; and **Hejaz, Hatem A**. (**2024**) "Exploring the Potent Antioxidant and Antibacterial Properties of Rosmarinus Officinalis L. Leaf Extract: Health-Promoting Benefits of Rosemary Leaf Extract," Palestinian Medical and Pharmaceutical Journal: Vol. 9 : Iss. 4, Article 2. Available at: https://doi.org/10.59049/2790-0231.1183

•Hatem A Hejaz, Atul Purohit A, Barry Potter. Synthesis and biological activities of flavonoid sulfamates as steroid sulfatase inhibitors. Journal of Medical Pharmaceutical and Allied Sciences; **2023**, 12(5):6025-6037.

•Hejaz HA. Knowledge and Attitudes towards Antibiotic Usage. Jordan Journal of Pharmaceutical Sciences. 2023 Jul 24;16(2):447-.

•Hejaz, H. A. (2023). Knowledge and Attitudes towards Antibiotic Usage. Jordan Journal of https://doi.org/10.35516/jjps.v16i2.1486Pharmaceutical Sciences, 16(2), 447.

•Hejaz HA and Asia MR. Potential Adverse Effects and Perceptions Following COVID-19 Vaccination among Palestinian Population. BioMed Res J, 2023 7(1): 579-590 https://www.researchgate.net/publication/369736317\_Potential\_Adverse\_Effects\_and\_Perceptions\_Following\_CO VID-19\_Vaccination\_among\_Palestinian\_Population

•Jabbarin H, Nawajah I, **Hejaz HA**. Knowledge, Attitude, Awareness, and Perceptions among Physicians toward Antibiotic Resistance in Hospitals in South Palestine. Avicenna J Med. **2023** Mar 24;13(1):49-55. doi: 10.1055/s-0043-1764374.

•Hatem A Hejaz, Reem Sabbobeh, Nouraldin Halayqa, Ali Jahajha, Saleh Abu-Lafi. Minerals Analysis of *Salvia palaestina* Leaves: Quantification and Detection; Journal of Plant Sciences, **2022**; 17(2): 53-61. DOI: 10.3923/jps.2022.53.61

•Hatem A Hejaz, Inad Nawajah, Maaly Wredat, Walaa Melhem. Knowledge, attitude, and practice toward the novel coronavirus-2019 (COVID-19) outbreak: A cross-sectional study in Palestine. Adv Biomed Health Sci 2022; 1(3):162-174. DOI:10.4103/abhs.abhs\_16\_22.

•Hatem A Hejaz, Alaa Khraiwesh, Halima Karma, Inass Nassar, Baha Halawani. The Awareness and Knowledge of Palestinian Pharmacists about Pediatric Doses. Journal of Medical Sciences; **2022**; 22(1):29-43. DOI: 10.3923/jms.2022.29.43.

•Hatem A Hejaz, Bara'a Shalaldeh, Taima Alnatsheh, Ameera Zalloum. Novel Coronavirus Disease (Covid-19): Guidelines and Protocols of the Pandemic. Kuwait Medical Journal (KMJ), **2022**; 54 (1): 1 - 26. Available from: <u>https://www.kma.org.kw/uploads/versions/TQRRDMHQCANRBLWFCNZYTHYP.pdf</u>.

•Hatem A Hejaz, Isra' Abuzaina, Reem Naser Aldeen, Sondos Saad. Currently Used and New Molecular Markers for Thyroid Cancer Diagnosis. Middle East Journal of Cancer, **2022**; 13(2):193-215. DOI: 10.30476/mejc.2022.87060.1392.

•Hatem A Hejaz, Isra' Abuzaina, Reem Naser Aldeen, Sondos Saad. Currently Used and New Molecular Markers for Thyroid Cancer Diagnosis. Middle East Journal of Cancer, **2022**; 13(2):193-215. DOI: 10.30476/mejc.2022.87060.1392.

•Alaa Khraiwesh, Aseel Bradea1, Anwar Jaradat, **Hatem A Hejaz**. Fertility Medication Uses and their Effect on Mothers and Children. Journal of Applied Sciences; **2022**; 22(1):8-21. DOI: 10.3923/jas.2022.8.21.

•Hatem A Hejaz, Raghad A Fallah, Rawand Al-Jabari, Duha Z Abdeen, Maha Jabari. Knowledge, Attitudes, and Acceptance toward Coronavirus Disease 2019 Vaccine. Scholars Academic Journal of Pharmacy 2021; 10(12): 213-224. DOI: 10.36347/sajp.2021.v10i12.003.

•Hatem A Hejaz, Fatima Al-Mohtaseb, Noor Abu Omar, Baha Halawani. Continuing Pharmaceutical Education: The Extent of the Conviction and Applicability in the Palestinian Pharmaceutical Community. International Journal of Natural Sciences: Current and Future Research Trends **2021**; 11(1), 11-23. Retrieved from https://ijnscfrtjournal.isrra.org/index.php/Natural\_Sciences\_Journal/article/view/1036.

•Rozan Attili, **Hatem A Hejaz**, Ghaleb Bouti, Zahra Abu Fara, Hadeel Allan, Marwa Tamimi. Monocytes and Lymphocytes Prognosis tools among Stroke Patients. Innovare Journal of Medical Science, **2021**; Vol 9, Issue 4, 18-26. DOI: http://dx.doi.org/10.22159/ijms.2021v9i4.39592.

•Hatem A Hejaz, Khulood Skafe, Suzan Awawdeh. Knowledge Awareness and Attitude of Women toward Epidural Anesthesia during Labor. Journal of Drug Delivery & Therapeutics. **2020**; 10(5-s):1-18. http://dx.doi.org/10.22270/jddt.v10i5-s.4333.

•Hatem A Hejaz, Ayat Kanan, Mahmoud Al-Muhtaseb, Ameer Jabari. Development and Characterization of Paracetamol Medicated Lollipop. Pharmaceutical Technology in Hospital Pharmacy, **2020**; 5(1):1-8. DOI: 10.1515/pthp-2020-0012.

•Hatem Hejaz Palestinian strategies, guidelines, and challenges in the treatment and management of coronavirus disease-2019 (COVID-19). Avicenna Journal of Medicine **2020**; 10:135-62. DOI: 10.4103/ajm.ajm\_171\_20.

•Hejaz HA, Zalloum A, Shalaldeh B, Alnatsheh T, Attili R. Novel Coronavirus Disease-2019: Epidemiology, Diagnosis, Therapeutics and Guideline Protocol for Disease Management in Different Countries. Iraq Med J 2020;4(2). DOI: https://doi.org/10.22317/imj.v4i2.796. Available from: https://iraqmedj.org/index.php/imj/article/view/796

•Rozan Attili, **Hatem A Hejaz**. The correlation of matrix metalloproteinase-9 with stroke and prevalence, risk factors, and knowledge of stroke among Palestinians. Innovare Journal of Medical Science, 2020; Vol 8, Issue 6, 1-7. DOI: http://dx.doi.org/10.22159/ijms.2020.v8i6.39593.

•Hatem A Hejaz, Abo Arqoup Dalia, Abu Znaid Hiba, Swaity Hiba, Rabai Thara'a, and Basheer-Salimia Rezq. A review on corona virus disease (COVID-19). Hebron University Research Journal; **2020**; Vol.(9), pp.(45-87). Available from: https://www.hebron.edu/index.php/en/a-natural-sciences/author/562-hatem-a-hejaz.html.

•Rozan Attili, **Hatem A Hejaz**, Asmaa Alkomi, Razan Jubeh, Safaa Erjoub, Hanaa Aldraweesh, Haya Alawawdah. Secondary hyperparathyroidism among end-stage renal disease patients. Innovare Journal of Medical Science, **2020**; Vol 8, Issue 6, 1-4. DOI: http://dx.doi.org/10.22159/ijms.2020.v8i6.39598.

•Hatem A Hejaz. Treatments and management of coronavirus disease 2019 (Covid-19). International Journal of Medical Science and Diagnosis Research (IJMSDR) **2020**; Volume 4, Issue 7; Page No. 52-71 Available from: https://www.ijmsdr.com/index.php/ijmsdr/article/view/622.

•Hejaz H. Carbonic anhydrase Inhibitors for treatment of Cancer. International Journal of Cancer and Treatment, Vol: 2, Issu: 2 (15-51); 2019. Available from: https://www.researchgate.net/publication/344692791\_Carbonic\_anhydrase\_Inhibitors\_for\_Treatment\_of\_Cancer. •Muammar Shaheen, **Hatem Hejaz.** Determinants of Iron Supplement Non-adherence among Young Pregnant Women in Southern Wet-Bank: Awareness of Anemia and Iron –Folic Acid Supplements. European Journal of Pharmaceutical & Medical Research, **2019**; 6 (10): 74-83. Available from: https://www.ejpmr.com/home/abstract\_id/5665.

•Rozan Attili, Ayman Hussein, Hilal Odeh and **Hatem Hejaz.** Prevalence of Thrombophilia in Palestine and the Association of Thrombophilic Gene Polymorphisms with Recurrent Pregnancy Loss. Research Journal of Obstetrics and Gynecology; **2019**; 12 (1): 6-10. DOI: 10.3923/rjog.2019.6.10.

•Rozan Attili, Muammar Shaheen, **Hatem Hejaz**. Prevalence of Genetic Cancers among Public in Palestine: Genetic trends and association with Matrix Metalloproteinase -9 as a Diagnostic Biomarker. Journal of Clinical and Medical Science; **2019**, Vol. 2.1; 1-8. (https://www.innovationinfo.org/journal/article\_archive)

•Rozan Attili/ Abedalkhader, Ayman Hussein, Hilal Odeh and **Hatem Hijaz**. Prevalence and Comparison of HLA-B27 among Ankylosing Spondylitis Patients in Palestine and Arab Population. Journal of Clinical and Medical Sciences. **2018**; Volume 2, (1) 1-4. Available from: https://www.walshmedicalmedia.com/abstract/prevalence-andcomparison-of-hlab27-among-ankylosing-spondylitis-patients-in-palestine-and-arab-population-25459.html

•Rozan Attili/ Abedalkhader, Ayman Hussein, Hilal Odeh and **Hatem Hijaz**. Prevalence and Comparison of HLA-B27 among Ankylosing Spondylitis Patients in Palestine and Arab Population. Journal of Clinical and Medical Sciences. **2018**; Volume 2, (1) 1-4. Available from: https://www.walshmedicalmedia.com/abstract/prevalence-andcomparison-of-hlab27-among-ankylosing-spondylitis-patients-in-palestine-and-arab-population-25459.html

•Rozan Attili/ Abedalkhader, Ayman Hussein, Hilal Odeh and **Hatem Hijaz**. Prevalence and Comparison of HLA-B27 among Ankylosing Spondylitis Patients in Palestine and Arab Population. Journal of Clinical and Medical Sciences. **2018**; Volume 2, (1) 1-4. Available from: https://www.walshmedicalmedia.com/abstract/prevalence-and-comparison-of-hlab27-among-ankylosing-spondylitis-patients-in-palestine-and-arab-population-25459.html

•Reem Sabbobeh, **Hatem Hejaz**, Ali Jahajha, Suha Al-Akhras, Hashem Al-Jaas and Saleh Abu-Lafi. Antioxidant an Antimicrobial Activities of the Leaf Extract of *Salvia palaestina*. Journal of Applied Pharmaceutical Science, **2016;** Vol. 6 (01), pp. 076-082. Available from: https://japsonline.com/admin/php/uploads/1752\_pdf.pdf.

•Hatem Hejaz, Reem Sabbobeh, Hashem Al-Jaas, Ali Jahajha and Saleh Abu-Lafi. Essential Oil Secondary Metabolites Variation of Salvia palaestina Leaves Growing wild from. Different Locations in Palestine. Journal of Applied Pharmaceutical Science, **2015**; 5(11): 084-089. Available from: https://pdfs.semanticscholar.org/1157/164cd46bdfc0b2db1cf4abca0016e5b99c54.pdf.

•Hejaz H., Karaman R. "Drugs Overview" Common Used Drugs - Uses, Side Effects, Bioavailability and Approaches to Improve It, Karaman, R. (editor) 2015, pp 1-40, Nova Science Publishers, NY, USA (ISBN: 9781634821445). DOI: https://doi.org/10.1007/s00894-011-1040-5

•Khdour MR, Hallak HO, **Hejaz H**, Shaeen M, Dweib M. Patterns of NSAIDs Use in Palestinian Mid-Territories: A prospective Study of Ambulatory Patients in Outpatient Pharmacies. Curr Clin Pharmacol. **2014** *Feb*;9(1):10-6

•Hejaz H, Karaman R, Khamis M. Computer-assisted design for paracetamol masking bitter taste prodrugs. J Mol Model. **2012** Jan 18(1): 103-14.

•Reem Sabbobeh, **Hatem Hejaz**, Hashem Al-Jaas, Ali Jahajha, and Saleh Abu-Lafi. Phytochemical Analysis of Cultivated and Wild *Salvia Palaestina* using GC-MS: A comparative study. World J Pharm Sci **2015**; 3(12): 2348-2356

•Leese MP, **Hejaz HA**, Mahon MF, Newman SP, Purohit A, Reed MJ, Potter BV. A-ring-substituted estrogen-3-O-sulfamates: potent multitargeted anticancer agents. Journal of Medicinal Chemistry. **2005** Aug 11;48(16):5243-56.

•Hejaz HAM, Woo LWL, Purohit A, Reed MJ and Potter BVL. Synthesis, *in vivo* activity of Benzophenone-based inhibitors of steroid sulfatase. Bioorganic & Medicinal Chemistry **2004**; 12: 2759-2772.

•Purohit A, Woo LWL, Barrow B, **Hejaz HAM**, Nicholson, Potter BVL and Reed MJ. No-steroidal and steroidal sulfamates: New drugs for cancer therapy. *Molecular and Cellular Endocrinology* **2001**; 171(1-2):129-35.

•Singh A, Purohit A, **Hejaz HAM**, Potter BVL and Reed MJ. Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-*O*-sulfamate. *Molecular and Cellular Endocrinology* 2000; 160; 61-66.

•Purohit A, **Hejaz HAM**, Singh A, Walden L, MacCarthy-Morrogh L, Packham G, Potter BVL Reed MJ. 2-Methoxyestrone-3-*O*-sulfamate: a novel drug for cancer therapy. *International Journal of Cancer* **2000**; 85; 584-589.

•MacCarthy-Morrogh L, Townsend PA, Purohit A, **Hejaz HAM**, Potter BVL, Reed MJ, and Packham G. Differential effects of estrone and estrone-3-*O*-sulfamate derivatives on mitotic arrest, apoptosis, and microtubule assembly in human breast cancer cells. *Cancer Research* **2000**; 60 (19): 5441-5450.

•Purohit A, Hejaz HAM, Woo LWL, van Strien AE, Potter BVL and Reed MJ. Recent advances in the development of steroid sulphatase inhibitors. *Journal of Steroid Biochemistry and Molecular Biology* **1999**; 69; 227-238.

•**Hejaz HAM**, Purohit A, Reed MJ, and Potter BVL. Synthesis and biological activity of the superestrogen (*E*)-oximino-3-*O*-sulfamoyl-1,3,5(10)-estratriene: X-ray crystal structure of (*E*)-oximino-3-hydroxy-1,3,5(10)-estratriene. *Journal of Medicinal Chemistry* **1999**; 42; 3188-3192.

•Woo LWL, Howarth NM, Purohit A, **Hejaz HAM**, Reed MJ and Potter BVL. Steroidal and non-steroidal sulfamates as potent inhibitors of steroid sulphatase. *Journal of Medicinal Chemistry* **1998**; 41; 1068-1083.

•Purohit A, Veron KA, Wagenaar Hummelinck AE, Woo LWL, **Hejaz HAM**, Potter BVL, and Reed MJ. The development of A-ring modified analogues of oestrone-3-*O*-sulphamate as potent steroid inhibitors with reduced oestrogenicity. *Journal of Steroid Biochemistry and Molecular Biology* **1998**; 64; 269-275.

•Acute and Subchronic Toxicity of the Plant Extract NASFIT. http://nasfit.net/toxity%20study.html

•1 atents: inventor of the following patent	
1. US8030296 B2 (2011)	2. US 2006/0281719 A1 (2006)
3. WO0144268 (2001)	4. US 2003/0134829 A1 (2003)
5. US2003225051 (2003)	6. US 6,858,597 B2 (2005)
7. DK1237902T3 (2006)	8. US 2006/0281719 A1 (2006)
9. US8030296 B2 (2011)	

#### •Patents: Inventor of the following patents

# **Teaching Interests: -**

<u>**Teaching philosophy:**</u> My basic teaching philosophy is to be enthusiastic about my subject, honest about potential confusion, and unambiguous in my explanations. I involve students in every lecture through a variety of mechanisms (call-and-response, intimate tutorials in which the students tell each other the answers using the chalkboard and I act as a facilitator, spot-the-trend checks, student papers/seminars, etc.). I try to make students feel that the lecture could not take place without them. I extensively use clear handouts so that the principles, not the details, are emphasized as being of importance. I de-emphasize memory work and stress the importance of integrating knowledge in the problem sets and exams (I tell the students this). Regurgitation is not part of my teaching philosophy.

## •Subjects Taught:-

1. Medicinal chemistry-I, II & III	2. Introduction to pharmacy/calculations
3. Clinical nutrition and diet therapy	4. Pharmacology for nurses
5. Natural products and phytopharmacy	6. Pharmacognosy
7. Pharmaceutical Organic Chemistry-I & II	8. Pharmaceutical Technology
9. General Chemistry	10. Pharmaceutical and Instrumental Analysis
11. Biochemistry I & II	12. Drug Design
13. Drug Metabolism	14. Spectroscopy
15. Toxicology	16. Spectroscopic Interpretation of unknown
17. Industrial Pharmacy	18. Stereochemistry

19. Nutrition & Medicine	20. Physical Pharmacy
21. Psychopharmacology	22. Introduction to Pharmacy
23. Pharmaceutical Analysis-I	24. Pharmaceutical Technology
25. Pharmaceutics-I	26. Medicinal and Biological Chemistry
27. Spectroscopy	28. Pharmaceutical and Instrumental Analysis
29. Food & Medicine	30. Medicinal and Biological Chemistry
31. Phytochemistry	32. First Aid & Public Health
33. Pharmaceutical Chemistry Labs	34. Organic Chemistry Labs
35. Medicinal Chemistry Labs	36. Pharmaceutical Calculations and Compounding Labs
37. Pharmacognosy Labs	38. Pharmaceutical Technology Labs
39. General Chemistry Labs	40. Research in Pharmaceutical Sciences
41. Pharmaceutical Training	42. Cosmetics Science
43. Drug Discovery	44. Pharmaceutical Clinical Biochemistry

#### **Conferences:-**

•The 9th International Pharmaceutical Conference 2024 (ZIPC2024). Oral presentation: "An *in vitro* Anticoagulant Effect of Aqueous Extract of Sumac *Rhus coriaria* L.". 16<sup>th</sup> and 17<sup>th</sup> of October 2024, Amman, Jordan.

•The 8th International Pharmaceutical Conference 2022 (ZIPC2022). Oral presentation: "Knowledge and attitudes towards antibiotic usage". 18<sup>th</sup> and 19<sup>th</sup> of October 2022, Amman, Jordan.

•The 10th Palestinian Pharmaceutical Conference. The pharmacy profession and the challenges it faces between the present and the future. Palestine Pharmacists Syndicate- 28-30 September 2022 Ramallah.

•ERASMUS+ INTERNATIONAL STAFF WEEK: Partnerships, Employability and Student Engagement; October 2019, Bradford University, Bradford-UK.

•The 7<sup>th</sup> International Pharmaceutical conference (ZTIPC 2019), Oral presentation: Prevalence of Depression Among Palestinian Adults With Diabetes Mellitus: A cross-sectional study. 6<sup>th</sup> -7<sup>th</sup> November 2019, Amman, Jordan.

•The 9<sup>th</sup> Palestinian Pharmaceutical Conference; "Pharmacy Profession-Realities & Challenges"; Palestine Pharmacists Syndicate, 12-15 September 2018, Bethlehem.

•The 8<sup>th</sup> Palestinian Pharmaceutical Conference; "Toward the Development of the Professional & Scientific Performance of Pharmacy Profession and Together in Supporting Our National Pharmaceutical Industry & Institution" Palestine Pharmacists Syndicate, Ramallah, 3-5 May 2016

•Malta VII Conference. Oral presentation: Flavonoid Sulphamates as Potent Steroid Sulphatase Inhibitors for Treatment of Breast Cancer. Rabat, Morocco, November 15<sup>th</sup> -20<sup>th</sup>, 2015.

•Medicines in Palestine, Oral presentation:"Drug Development and Review Process" Palestinian Red Crescent, Ramallah April 25, 2014.

•The 7<sup>th</sup> Palestinian Pharmaceutical & the 3<sup>rd</sup> Clinical Pharmacy Conference; "Good Pharmacy Practice Supports Health and Economical Security" Palestine Pharmacists Syndicate, Ramallah 15<sup>th</sup>-17<sup>th</sup> May 2013

•The 26<sup>th</sup> General Arab Phamacists' Union Conference & 12<sup>th</sup> Jordan Pharmacists' Association Conference 10<sup>th</sup>-12<sup>th</sup> April 2008.

•The Fourth Palestinian Chemistry Conference, Alquds University, Jerusalem 14-15 April 2008.

•The 7<sup>th</sup> International Saudi Pharmaceutical Conference, Saudi Pharmaceutical Society, Riyadh-K.S.A.; March 19-21, 2007

•The 1<sup>st</sup> Riyadh International Dental & Health Care Meeting and 1<sup>st</sup> Arab International Dental Education Meeting. Riyadh College of Dentistry & Pharmacy-Riyadh-K.S.A.; November 11-13, 2006

•The 6<sup>th</sup> Jordanian Chemical Conference (6<sup>th</sup> JCC), Jordan Chemical Society & Faculty of Science and Arts, Department of Chemistry, Hashemite University; Zarqa-Jordan; December 12, 2005.

•Chemistry Between Academia and Industry, Jordan Chemical Society & Faculty of Science, Department of Chemistry, Jordan University; Amman-Jordan; October 1, 2005.

•The 11<sup>th</sup> Jordanian Pharmaceutical Conference; Jordan Pharmaceutical Association; Amman-Jordan; September 28-30, 2005.

•European Pharmaceutical Regulatory System, Petra University, Amman-Jordan; May 3-4, 2005.

•Dubai International Pharmaceuticals & Technologies Conference & Exhibition (**DUPHAT**), Dubai, March 1-3, 2003.

•The 6<sup>th</sup> Scientific Congress of the Association of Colleges of Pharmacy in the Arab World; UAE; October 19-21, 2002.

•The 1<sup>st</sup> International Conference of Faculty of Pharmacy & Health Sciences; Ajman University of Science & Technology (**Technosphere 2002**), UAE; October 19-21, 2002.

•Dubai International Pharmaceuticals & Technologies Conference & Exhibition (**DUPHAT**), Dubai, March 9-11, 2002.

•Dubai International Pharmaceuticals & Technologies Conference & Exhibition (**DUPHAT**), Dubai, April 22-24, 2001.

•Royal Society of Chemistry; Heterocyclic Chemistry Group; King's College London; England; UK. 8 January 1999.

•Royal Society of Chemistry; Heterocyclic Chemistry Group; Aston University; Birmingham; England; UK. 21 September 1998.

•XV<sup>th</sup> EFMC International Symposium on Medicinal Chemistry, Edinburgh, Scotland, UK. 6-10 September 1998. (*Poster presented*).

•Royal Society of Chemistry; Heterocyclic Chemistry Group; King's College London; England; UK. 9 January 1998.

•Medicinal Chemistry Group of the Atlantic ARC; University of Rennes; Rennes; France. 10-11 July 1997. (*Poster presented*).

•Royal Society of Chemistry; Heterocyclic Chemistry Group; King's College London; England; UK. 3 January 1997.

•3rd Bath International Symposium on Medicinal Chemistry Group; University of Bath; Bath; England; UK. 22-24 September 1996. (*Poster presented*).

## **Other Information:-**

•Member of Deans council, Arab American University; 01/09/2022- till now.

•Head of the Central Committee for University Ranking, Hebron University; 16/3/2022-1/9/2022.

•Coordinator of Graduation Program (*Master of Pharmacognosy and Medicinal plants*), Department of Pharmacy, College of Pharmacy & Medical Sciences-Hebron University; since 1/9/2019- 1/9/2022.

•Editor of Hebron University Research Journal (Natural Sciences), Hebron University; 26/8/2018- 1/9/2022

•Member of University council, Hebron University; 25/8/2019-1/9/2022

•Member of University Academic council, Hebron University; 25/8/2019- 1/9/2022

•Member of University Scientific council, Hebron University; 25/8/2019- 1/9/2022

- •Member of Department of Pharmacy Council, Hebron University. 26/8/2018- 1/9/2022
- •Member of Department of Pharmacy Council, Birzeit University. 5/9/2017-26/8/2018
- •Member of Faculty of Pharmacy Council, Al-Quds University. 1/8/2007-1/9/2017

•Member of University council, Al Quds University; 1/8/2012-1/8/2014.

•Coordinator of Timetable and Examination, Faculty of Pharmacy, Alquds University, 1/9/2010-1/9/2017

•Coordinator of Graduation Program, Faculty of Pharmacy, Alquds University, 1/9/08-1/9/2013

•Member of University Academic council, Al Quds University; 1/9/07-1/9/2010 & 1/8/2012- 1/8/2014

•Member of Scientific Committee for Health sciences Affairs; 1/9/07-1/9/2017

•Chairman of Pharmacy & Medical Laboratory Technology Department; 15/4/2006-12/7/06-1/3/07; Riyadh College of Dentistry & Pharmacy; Riyadh-Kingdom of Saudi Arabia.

•Head of Pharmaceutical Chemistry Department; The Specialized Pharmaceutical Research Co. Ltd. (STD); Amman-Jordan; 1/9/04-1/5/06

•Head of Timetable and Examination Committee, Faculty of Pharmacy and Medical Sciences, Amman University.

•Member of both the Library and curriculum and syllabus committee, Faculty of Pharmacy Al-Quds University. Faculty of Pharmacy and Medical Sciences, Amman University

•Head, of Department, *Department of Pharmaceutical Chemistry & Pharmacognosy*; Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology; 2001-2003.

•Head, of the Central Research and Postgraduate Committee, Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology.

•Timetable and Examination Coordinator, Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology.

•External Relations and Culture Affairs Coordinator, Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology.

•Referee for the Scientific Journal of An Najah National University, Nablus, Palestine

•Member of Central stocktaking and Budget Committee, Faculty of Pharmacy and Health Sciences, Ajman University of Science and Technology.

•**Thesis/ Graduation Projects:** Supervisor of M.Pharm students (Pharmacognosy & Medicinal Plants Program) & Supervised many graduation projects of B.Pharm. students. Have been an external examiner of B. Pharm. & M. Pharm. students for different universities.

•Organization: *Head of the Information, Media and Promotion Committee for* The 6<sup>th</sup> Scientific Congress of the Association of Colleges of Pharmacy in the Arab World; UAE; and The 1<sup>st</sup> International Conference of Faculty of Pharmacy & Health Sciences; Ajman University of Science & Technology (**Technosphere 2002**), UAE; October 19-21, 2002.

•Pharmaceutical Associations: Member of Jordan Pharmaceutical Association, since August 1994 till now

•Languages: Arabic and English.

•Achievements: •Awarded Three Scholarships to study Bachelor of Pharmacy (1989-1993); Master of Pharmacy (1993-1995) and Ph.D. (1995-1998) respectively. Obtained First Class with honor and First Class with distinction in B.Pharm. and M.Pharm. respectively.

•Clinical Trials: Different Drugs are currently under Clinical Trials for the Treatment of Cancer.

•Hobbies: Sports (Soccer, Basketball, and Volleyball), Reading, Chess and Traveling.

•Driving License: KSA, UAE, Jordan, and UK & Palestine.

**References:-**

# References provided upon request

I would describe myself as a very determined and highly motivated person. I do take my job seriously but I can see things in perspective and believe I am quite easy-going to work with. I am an optimist rather than a pessimist - but I am also a realist and me coupe well when the going gets tough; I am very good at finding solutions to problems. I would like to say I am a positive and enthusiastic, creative, hard worker, simple, fair, and social.